The annual GETECCU Congress in Spain became the epicenter of a seismic shift in the landscape of Inflammatory Bowel Disease (IBD) treatment. Evinature, the pioneering company behind CurQD®, a revolutionary nutraceutical, joined forces with Adacyte officials to present their breakthrough therapy to the IBD community in Spain. The response was nothing short of astounding.
GETECCU, or the Grupo Español de Trabajo de Crohn y Colitis Ulcerosa (Crohn’s Disease and Ulcerative Colitis Spanish Working Group), has been at the forefront of IBD research and care for the past two decades. It encompasses various areas of interest, including education, clinical practice, scientific advancement, and social support for IBD patients.
Joining the Adacyte officials are Evinature’s co-founders, Apan Amos Damri, Nir Salomon, and Professor Shomorn Ben-Horin, to host a symposium on the integration of CurQD® into clinical IBD practices. The impact of their presentation was immediate and resounding.
“We were blown away by the high demand and interest shown in CurQD®,” says Apan. “The treatment is being fully embraced by leading IBD doctors not only in the U.S. but here in Europe, promising great advances for the IBD community.”
CurQD® has also produced tangible results in clinical trials, significantly improving remission rates among IBD patients. As Nir rightly pointed out, “Now, it’s about establishing the correct medical positioning of this treatment – a huge step for nutraceuticals in the IBD field.”
The CurQD® Launch Via Adacyte
The next milestone in this journey is the availability of CurQD® to patients in Spain, scheduled to launch via Adacyte in just one month. This launch comes with a commitment to providing free online assessments, localized Clinic Support, and web services dedicated specifically to Spanish-speaking patients, ensuring that accessibility and support are readily available.
Nir emphasized the enthusiasm among the Spanish medical community, saying, “It was eye-opening to witness how much CurQD has taken off there. Our booth was flooded by doctors who had lists of patients waiting to access this treatment. The head of the IBD medical society told me it was the most exciting advance they’d seen in years.”
“Leave No Patient Behind”
Beyond the conferences and presentations, Evinature’s leadership trio remained grounded in their mission. Amid the whirlwind of meetings and discussions, the CEO, Chief Medical Officer, and Head of R&D took the time to personally address the case of a struggling patient.
The trajectory of CurQD® from inception to global acceptance has been remarkable. But despite this success story, the Evinature team reiterated that it’s not just about innovation but also about unwavering dedication to improving the lives of IBD patients.
“We were left contemplating the best way to maintain integrity in our work,” Nir said. “CurQD is growing, and it’s happening quickly. In less than a year, it stands side-by-side with huge pharmaceutical brands as a valid and desirable treatment option. But now, more than ever, it’s vital we stick to our roots, continue prioritizing every single case, and leave no patient behind.”
The integration of CurQD® into clinical IBD practices in Spain marks a pivotal moment in the fight against Crohn’s Disease and Ulcerative Colitis. It is a testament to the power of innovation, collaboration, and patient-centric care in revolutionizing healthcare and offering hope to individuals living with IBD. As CurQD® continues to shine, it carries with it the promise of a brighter future for IBD patients worldwide.
